Fetzima (Levomilnacipran) is a medication prescribed for the treatment of major depressive disorder in adults. Although it is similar to the drug Savella (Milnacipran), Fetzima exhibits unique pharmacodynamics in that it functions as a serotonin-norepinephrine reuptake inhibitor (SNRI) with a 2-fold affinity for norepinephrine reuptake inhibition – relative to serotonin reuptake inhibition. In other words, …
Fetzima (Levomilnacipran), is a serotonin-norepinephrine reuptake inhibitor (SNRI) that was approved by the United States FDA in 2013 for the treatment of major depressive disorder. It was engineered to be a spinoff (or some might suggest an upgraded or slightly modified version) of the drug Savella (Milnacipran). Comparatively, Fetzima solely contains the levorotatory enantiomer of …
Fetzima (Levomilnacipran) is a serotonin-norepinephrine reuptake inhibitor that was approved by the FDA in 2013 to treat major depression. It is similar to the older drug milnacipran, but contains the “levo”-stereoisomer – making it slightly different. This antidepressant is regarded as being significantly different from other SNRIs in that it inhibits norepinephrine reuptake to a greater …
When a new antidepressant drug is released, everyone wants to be the first to try it. In most cases, people seem to always believe that newer will equal better in terms of depression relief. In most cases, when new drugs get approval to treat depression, they are backed by some heavy marketing, which further brainwashes …
SNRIs (Selective Serotonin Reuptake Inhibitors) are also known as dual-reuptake inhibitors because they prevent the reuptake of multiple neurotransmitters in the brain. Most of the second-generation antidepressants are classified as “SSRI,” meaning they focus solely on preventing the reuptake of serotonin. SNRI drugs continue to prevent the reuptake of serotonin, but also focus on another …